Tirzepatide Vial | 120mg
£90.00
Sale price
£90.00
Regular price
Skip to product information
Weekly Injection
Tirzepatide Vial | 120mg
Starting at £80 per vial with a
subscription plan
120mg Tirzepatide research solution, precisely dosed and independently verified by Janoshik Analytical. Dual GIP and GLP-1 receptor agonist studied extensively in published clinical trial settings. Designed for research purposes.
Meet the Tirzepatide Pen
-
Ready-to-use research solution
-
≥99% purity, third-party verified
-
Pharmaceutical grade research formulation
-
Free shipping on all UK orders
Pickup currently not available
Tirzepatide | A synthetic dual hormone receptor agonist targeting GIP and GLP-1 receptors simultaneously. Studied extensively in controlled clinical trial settings — including the landmark SURPASS and SURMOUNT trial programs — for its role in metabolic regulation, insulin sensitivity and adipose tissue research models.*
Our compounds are manufactured by Homopeptides and every batch is independently analysed by Janoshik Analytical before reaching you. Janoshik are one of the most respected third-party testing laboratories in the peptide research space — their verification gives you confidence in every order.
This compound is supplied as a lyophilised powder and is intended for reconstitution prior to laboratory use. Store at 2–8°C in a refrigerator, protected from light, heat and moisture. Reconstitute only using an appropriate research-grade diluent immediately before use. Once reconstituted, stability will depend on the selected diluent and storage conditions. For laboratory and research purposes only.*
All orders are dispatched within 1–2 business days. Compounds are packaged with temperature-controlled materials to maintain integrity during transit. Free shipping on all UK orders.
Featured reviews
Compounds trusted by researchers worldwide
Vytol compounds used by over 10,000 researchers across 50+ countries
Month 0
Month 3
"Exceptional quality and purity. The results speak for themselves in our research applications."
Sarah Mitchell
Verified review
Month 0
Month 6
"Consistent results across multiple trials. Vytol has become our trusted supplier for peptide research."
Prof. James Chen
Verified review
Month 0
Month 4
"Outstanding customer service and product documentation. Makes my research workflow seamless."
Dr. Emily Rodriguez
Verified review
Compounds built for
precision
Body weight reduction recorded in the SURMOUNT-1 Phase 3 trial over 72 weeks.
Of participants on tirzepatide 10mg and 15mg achieved at least 5% body weight reduction.*
*Based on published peer-reviewed in-vitro research. For research purposes only.
*Jastreboff AM et al. 'Tirzepatide Once Weekly for the Treatment of Obesity.' N Engl J Med. 2022;387:205–216. SURMOUNT-1 Phase 3 clinical trial, Eli Lilly. For research purposes only. Not for human use. Individual results not implied or guaranteed.
